Zenith Health Care Peer Comparison

BSE: 530665

₹3.15

₹-0.02 (-0.63%)

As on 06-Oct-2026IST

Market cap

₹17 Cr

Revenue (TTM)

₹11 Cr

P/E Ratio

107.1

P/B Ratio

2.2

Div. Yield

0 %

Edit

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	17	35,327	26,440	26,634	25,836
Revenue (₹ Cr)	11	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	0.16	414.00	288.22	-371.81	387.35
Net Margin (%)	1.42	11.23	14.79	-3.93	26.01
RoE (%)	2.11	8.38	29.77	-3.85	25.18
Price to Earnings	107.14	86.38	91.74	--	66.90
Price-To-Book	2.24	7.02	19.70	3.33	14.97

Income Statement (₹ Cr)

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	10.81	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	11.12	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	10.63	2,792.00	1,485.56	8,195.15	919.25
EBITDA	0.17	772.00	450.24	1,010.13	542.56
Depreciation	0.26	226.00	50.83	857.51	37.68
EBIT	-0.09	546.00	399.41	152.62	504.88
Interest	0.01	217.00	40.84	342.73	3.77
Other Income	0.32	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	0.22	463.00	371.35	-162.68	528.56
Provision for Tax	0.06	49.00	83.14	209.13	141.21
Profit after Tax	0.16	414.00	288.22	-371.81	387.35

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	7.42	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	0.00	1,712.00	202.03	5,044.14	42.40
Current Liabilities	3.56	1,622.00	835.87	4,758.28	230.82
Total Liabilities	10.99	8,578.00	2,326.71	17,723.32	1,983.96

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	3.10	5,343.00	519.60	10,211.52	1,026.85
Current Assets	7.45	2,606.00	1,681.81	7,191.66	881.27
Total Assets	10.99	8,578.00	2,326.71	17,723.32	1,983.96
Total Debt*	0.00	2,125.00	259.37	5,495.48	26.49
Net Current Assets	3.89	984.00	845.94	2,433.38	650.46
Contingent Liabilities	--	768.26	19.09	95.72	17.25

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-0.83	390.00	205.05	1,652.60	292.17
Cash Flow from Investing Activities	0.85	-241.00	-409.72	-826.03	-265.94
Cash from Financing Activities	-0.01	-54.00	283.07	-38.98	4.10
Net Cash Inflow / Outflow	0.01	95.00	78.39	787.59	30.33

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	0.33	6.79	29.22	1.24	32.42
ROE (%)	2.11	8.38	29.77	-3.85	25.18
ROA (%)	1.45	4.94	24.77	-2.21	21.93
EBIT Margin (%)	-0.83	15.32	20.63	1.66	34.54
Net Margin (%)	1.42	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-9.27	18.37	46.65	0.78	40.90
EBIT Growth (%)	77.78	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	246.30	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	246.29	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	0.24	13.47	144.31	0.33	26.03

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	107.14	88.65	90.33	-85.12	66.90
Price / Book Value	2.24	7.02	19.70	3.33	14.97
Dividend Yield (%)	0.00	0.00	0.09	0.00	0.08
EV/EBITDA	97.97	47.66	58.53	30.47	47.25
Market Cap (₹ Cr)	13.00	19,071.62	12,753.19	18,108.89	20,944.75

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.11	0.53	0.02
Short term debt to equity ratio	--	0.09	0.05	0.09	0.02
Current Ratio	2.09	1.61	2.01	1.51	3.82
Quick Ratio	1.27	1.06	1.14	0.87	2.82
Interest Coverage	38.00	3.13	10.09	0.53	141.16

	Zenith Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	19.35	16.50	26.28	23.44	24.80
Asset Turnover	0.99	0.43	1.66	0.55	0.83
Receivable days	78.28	58.75	40.13	78.20	88.98
Inventory Days	90.07	75.82	60.29	93.30	56.04
Payable days	124.95	186.21	232.47	226.14	99.95
Cash Conversion Cycle	43.40	-51.64	-132.04	-54.64	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.